Search

EHA Guidelines by Topic

AL Amyloidosis
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022)
Anemia
Recommendations regarding splenectomy in hereditary hemolytic anemias (2017)
Management of…

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

EPICOVIDEHA survey

COVID-19 infections in patients with Hematological Malignancies - Results from EHA-IDWP registry
EPICOVIDEHA is an international open web-based registry for patients with haematological malignancies infected with SARS-CoV-2,
The survey has been approved by the Institutional Review Board and Ethics Committee of the…

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more